Genesys Capital
Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 that invests as founding or lead investor in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, having raised over $400 million across five funds and executed 20 exits.
- Company typePrivate
- Founded2000
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Genesys Capital does
Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 by Damian Lamb and Kelly Holman. The firm invests exclusively in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, with deep operational ties to Canadian research institutions including McMaster University, the University of Toronto, and Queen's University. Genesys employs a create-and-build strategy, acting as founding investor in approximately 80% of its deals and assuming active board roles through the company-building phase; it has backed 44 portfolio companies and recorded 20 exits, headlined by Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4 billion USD) and Inversago Pharma (acquired by Novo Nordisk for $1.1 billion USD).
The firm's core offering is not a technology product but a specialized investment service combining capital deployment with strategic guidance, board leadership, and operational support to scientific founders. Revenue is generated through three mechanics typical of closed-end venture funds: (1) management fees on committed and deployed capital across its five funds, which together exceed $400 million in aggregate raises; (2) carried interest on profitable exits, of which the firm has realized at least 20; and (3) fund-raising proceeds from limited partners for successive vehicles, with Genesys Ventures IV (closed mid-2025) representing the largest fund to date. Recent lead investments include a $10.3M Series B1 in Enspire DBS Therapy (Jan 2026), a $21M co-led Series B in Feldan Therapeutics (Sep 2024), and a CAD $7.3M seed in Antegrade Medical (Oct 2025).
Genesys serves a single primary customer segment — clinical-stage and early-stage life sciences companies seeking growth capital and strategic partnership — and distributes capital exclusively through direct equity investment, typically as founding investor or lead investor in Series A rounds. The firm maintains a small, senior team of approximately nine professionals based at its Toronto headquarters, and pursues a regional North American investment thesis anchored in proximity to the Ontario research corridor.
Genesys Capital firmographics
Firmographics- Name
- Genesys Capital
- Legal name
- Genesys Capital
- Website
- https://genesyscapital.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Genesys Capital is a Toronto-based life sciences venture capital firm founded in 2000 that invests as founding or lead investor in early-stage biotechnology, pharmaceutical, and medical technology companies across North America, having raised over $400 million across five funds and executed 20 exits.
- Ownership category
- akta.pro rank
Genesys Capital industry classification
Industry- Product category
- Venture Capital - Life Sciences
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990), Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industries
- Healthcare & Life Sciences Growth Equity (FSANACAB), Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where Genesys Capital is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Genesys Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Venture Capital Returns: Genesys Capital generates returns through successful portfolio company exits (acquisitions and IPOs), management fees from venture capital funds, and carried interest on investment profits. The firm has achieved over 20 exits including major acquisitions like Fusion Pharmaceuticals (AstraZeneca, $2.4B) and Inversago Pharma (Novo Nordisk, $1.1B).
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Genesys Capital product offering
Product offeringCore offering
Genesys Capital is a life sciences venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies as a founding or lead investor in Series A rounds. The firm deploys capital from its venture funds (currently Genesys Ventures IV), provides strategic guidance, board leadership, and operational support to scientific founders, and has invested in 44 companies across its 25+ year history. It generates returns through portfolio company exits, including notable acquisitions such as Fusion Pharmaceuticals by AstraZeneca ($2.4B) and Inversago Pharma by Novo Nordisk ($1.1B).
Product overview
Genesys Capital is a life science venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies. As a VC firm, it does not offer traditional products or services in the SaaS sense; instead, it provides investment capital, strategic guidance, and operational support to portfolio companies. The firm has raised over $400 million across 5 early-stage venture funds, with 44 portfolio companies and 20 exits.
Differentiator
Problem solved
Functional benefit
Products and services
- Genesys Ventures IV LP Genesys Ventures IV LP is Genesys Capital's largest early-stage life sciences venture capital fund to date, from which the firm is currently investing into North American biotechnology, pharmaceutical, and medical technology companies as founding or lead investor in Series A rounds. Intended for limited partners seeking exposure to early-stage life sciences venture capital.
- Genesys Ventures I–III (Prior Early-Stage Venture Funds) Earlier Genesys Capital venture funds (Funds I–III) that deployed capital into North American early-stage biotechnology, pharmaceutical, and medical technology companies. Together with Fund IV, these funds constitute the firm's $400M+ raised across five early-stage venture funds. Intended for limited partners and institutional investors in life sciences venture capital.
Quantifiable outcome
- 20 successful exits achieved
- +2 more outcomes
Companies that use Genesys Capital
Customer profileSegments1 record
Ideal customer profiles1 record
Genesys Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genesys Capital partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor.
- Centre for Probe Development and Commercialization at McMaster UniversityminorDamian Lamb serves on the Board of the Centre for Probe Development and Commercialization at McMaster University, representing the firm's ongoing relationship with academic commercialization entities.
- Ontario Genomics Institute (OGI)minorJamie Stiff serves as an advisor to OGI, supporting genomics research commercialization in Ontario.
- Centre for Commercialization of Regenerative Medicine (CCRM)minorJamie Stiff serves as an advisor to CCRM, supporting commercialization of regenerative medicine technologies.
- Medicine by DesignminorJamie Stiff serves as an advisor to Medicine by Design, supporting stem cell and regenerative medicine research translation.
- Creative Destruction Lab (CDL)minorJamie Stiff serves as an associate with CDL, supporting early-stage company development and mentorship.
- BioteCanadaminorJamie Stiff volunteers as a board member for BioteCanada, the national industry association for biotechnology.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Genesys Capital competitors and assessment
Company assessmentDirect peers
- TVM Life Science Ventures: Canadian-headquartered venture capital firm investing in early-stage life sciences companies. Directly comparable in terms of fund size, geography, and create-and-build approach in biotech and medtech.
- Lumira Ventures: Toronto-based life sciences venture capital firm with a similar focus on early-stage Canadian biotech and medtech companies. Overlapping investment theses and LP base with Genesys Capital.
- Amplitude Ventures: Canadian life sciences venture firm focused on precision medicine and earlier-stage biotech. Comparable in size, mandate, and Canadian academic sourcing network.
Broad incumbents
- Versant Ventures: Established North American life sciences venture capital firm with a broader platform across biotech, medtech, and healthcare services. Comparable sector focus but materially larger fund sizes.
- 5AM Ventures: U.S. life sciences venture firm with similar early-stage biotech focus, including company formation out of academic research. Comparable origination strategy but larger fund scale.
- Atlas Venture: Boston-based life sciences VC with a create-and-build model for early-stage biotech companies. Closest comparable peer in approach and stage; operates at a larger fund size.
- OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across all stages of biotech, medtech, and healthcare services. Provides scale and stage benchmarks for the broader sector.
Emerging players
- Alexandria Venture Investments: Strategic venture arm of Alexandria Real Estate Equities, active in early-stage life sciences with strong academic sourcing in North America. Comparable origination profile with a different capital structure.
- Sectoral Asset Management: Healthcare-focused VC that co-invested with Genesys in Antegrade Medical. Comparable early-stage medtech orientation with their Medtech Ventures fund.
Regional players
- Bloom Burton & Co. Canadian healthcare-specialized investment bank and venture capital firm. Adjacent rather than direct overlap, but shares the Canadian life sciences ecosystem and similar founder relationships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Genesys Capital social profiles
Digital presenceGenesys Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genesys Capital leadership team
Management profileNumber of profiles
Profiles8 records
Genesys Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genesys Capital M&A and investment
M&A and investmentM&A
Investments37 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genesys Capital
What does Genesys Capital do?
Genesys Capital is a life sciences venture capital firm that invests in early-stage biotechnology, pharmaceuticals, and medical technology companies as a founding or lead investor in Series A rounds. The firm deploys capital from its venture funds (currently Genesys Ventures IV), provides strategic guidance, board leadership, and operational support to scientific founders, and has invested in 44 companies across its 25+ year history. It generates returns through portfolio company exits, including notable acquisitions such as Fusion Pharmaceuticals by AstraZeneca ($2.4B) and Inversago Pharma by Novo Nordisk ($1.1B).
Is Genesys Capital a public or private company?
Genesys Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Genesys Capital founded?
Genesys Capital was founded in 2000. It employs 1 to 10 people.
Where is Genesys Capital based?
Genesys Capital is headquartered in Toronto, Canada, in the North America region.
How does Genesys Capital make money?
One revenue line is on record: venture Capital Returns.
Who are Genesys Capital's main competitors?
Direct peers on record are TVM Life Science Ventures, Lumira Ventures and Amplitude Ventures. Broad incumbents are Versant Ventures, 5AM Ventures, Atlas Venture and OrbiMed. Emerging players are Alexandria Venture Investments and Sectoral Asset Management. Bloom Burton & Co. is listed as a regional player.
Does Genesys Capital have an API?
No public API is recorded for Genesys Capital.
What industry is Genesys Capital in?
Genesys Capital's product category is Venture Capital - Life Sciences. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525 and its SIC code is 6282.